Abstract: Background The number of patients age >65 years with malignant gliomas is increasing. Prognosis of these patients is worse compared with younger patients. To determine biological differences among malignant gliomas of different age groups and help to explain the survival heterogeneity seen in the NOA-08 trial, the prevalence and impact of recently established biomarkers for outcome in younger patients were characterized in elderly patients. Methods Prevalences of mutations of isocitrate dehydrogenase 1 (IDH1) and histone H3.3 (H3F3A), the glioma cytosine-phosphate-guanine island methylator phenotype (G-CIMP), and methylation of alkylpurine DNA N-glycosylase (APNG) and peroxiredoxin 1 (PRDX1) promoters were determined in a representative biomarker subset (n = 126 patients with anaplastic astrocytoma or glioblastoma) from the NOA-08 trial. Results IDH1 mutations (R132H) were detected in only 3/126 patients, precluding determination of an association between IDH mutation and outcome. These 3 patients also displayed the G-CIMP phenotype. None of the IDH1 wild-type tumors were G-CIMP positive. Mutations in H3F3A were absent in all 103 patients sequenced for H3F3A. MassARRAY analysis of the APNG promoter revealed generally low methylation levels and failed to confirm any predictive properties for benefit from alkylating chemotherapy. Neither did PRDX1 promoter methylation show differential methylation or association with outcome in this cohort. In a 170-patient cohort from The Cancer Genome Atlas database matched for relevant prognostic factors, age 65 years was strongly associated with shorter survival. Conclusions Despite an age-independent stable frequency of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation, tumors in this age group largely lack prognostically favorable markers established in younger glioblastoma patients, which likely contributes to the overall worse prognosis of elderly patients. However, the survival differences hint at fundamental further differences among malignant gliomas of different age groups. The number of patients > 65 years of age with malignant gliomas is increasing. Prognosis of these patients is worse compared to younger patients. To determine biological differences between malignant gliomas of different age groups and help to explain the survival heterogeneity seen in the NOA-08 trial, the prevalence and impact of recently established biomarkers for outcome in younger patients were characterized in elderly patients.
INTRODUCTION
Glioblastoma (WHO grade IV) is the most common intrinsic brain tumor. The prognosis for patients suffering from this disease remains dismal. Age in particular is a strong negative predictor for survival, resulting in a population-based median survival of elderly patients (i.e., older than 65 years) of less than 6 months 1 . As glioblastoma incidence is strongly increasing with age, soon more than half of all glioblastoma patients will be considered elderly 2 . Improving the therapy of these patients is therefore one of the major challenges in neurooncology 3 .
The standard of care in elderly patients is currently ill-defined. This is in part due to the exclusion of elderly patients in many clinical trials. The EORTC-NCIC trial, which defined concomitant and adjuvant radiochemotherapy with temozolomide as the standard of care, excluded patients older than 70 years 4 . In elderly patients receiving combined radiochemotherapy, treatment-associated toxicity seems to be higher compared to younger patients 5 . This especially holds true for radiation-related neurotoxicity, which demonstrates a clear agedependency 6, 7 . To date, involved-field radiotherapy alone is recommended as the standard first-line therapy after biopsy or resection in elderly patients 8 . However, due to the risk of radiation-induced neurotoxicity, temozolomide alone has been explored as a treatment option. Several studies have reported a median overall survival comparable to radiotherapy alone with only modest toxicity of temozolomide in this population 9, 10 . To directly compare radiotherapy alone versus temozolomide alone, the German Neuro-Oncology Working Group (NOA) conducted a randomized phase 3 trial (NOA-08) in elderly patients. This trial demonstrated a noninferiority of temozolomide (1 week on / 1 week off regimen) to focal radiotherapy. Importantly, hypermethylation of the O 6 -methylguanine-DNA methyltransferase (MGMT) promoter was established as a very strong predictive biomarker for temozolomide sensitivity in elderly patients with malignant glioma. Of note, even though median overall survival was short (8.6 months in the temozolomide group vs. 9.6 months in the radiotherapy group), in both treatment arms a subset of patients survived considerably longer than two years 11 .
Recently, several other molecular markers have been reported as being either prognostic or even predictive of benefit from specific therapeutic interventions in malignant glioma patients. In 2008, Parsons et al. discovered mutations in the isocitrate dehydrogenase 1 gene (IDH1) in a subset of glioblastoma patients 12 . Subsequently, mutations in either IDH1 or IDH2 have been identified in > 70% of WHO grade II and III gliomas and secondary glioblastomas 13 . In primary glioblastomas, IDH mutations are rare. Importantly, IDH mutations are associated with a significantly longer survival time compared to IDH wildtype tumors. Among grade III and IV gliomas pooled, IDH has a stronger prognostic impact than the WHO grade. In the same study, the authors also found that in patients with anaplastic astrocytoma and glioblastoma aged 60 years or older, IDH1 mutation is found in only 7.5% of the patients (11/146) 14 . APNG is a DNA base excision repair enzyme, which catalyzes removal of N3-methyladenine (N3-meA) and N7-methylguanine (N7-meG) from DNA, both of which can be caused by temozolomide. APNG expression is regulated through promoter methylation, and in patients with an unmethylated MGMT promoter receiving temozolomide, the subset of APNG negative tumors was reported to have a better prognosis. Peroxiredoxin 1 (PRDX1) is another interesting candidate, especially in the group of anaplastic astrocytomas. The PRDX1 promoter was found to be frequently hypermethylated in oligodendroglial tumors and secondary glioblastomas carrying a deletion of 1p/19q, leading to epigenetic down-regulation of PRDX1 expression 19 . In this study, silencing of PRDX1 in Hs683 glioma cells sensitized these cells both to temozolomide and radiotherapy in vitro.
The objective of our present study was to determine the prevalence and impact of recently defined biomarkers which are associated with survival, but were established in younger patients, in an elderly collective. We hypothesized that these biomarkers might help to explain the heterogeneity in survival seen in the NOA-08 population. However, as our study revealed that they are virtually absent in elderly patients, we assume that relevant molecular differences exist between malignant glioma of different age groups, which warrant further studies.
MATERIALS AND METHODS

Patients and DNA
This study comprised 126 patients of the NOA-08 collective, nine with anaplastic astrocytomas (7.1%) and 117
with glioblastomas (92.9%). All patients were 65 years or older 11 .
DNA from fresh-frozen paraffin-embedded (FFPE) tissue was extracted using the Invisorb Genomic DNA Kit II (Stratec Molecular, Berlin, Germany). Before DNA extraction, specimens were histopathologically reviewed and tumor content > 80% was confirmed.
To complement our subset with a series of tumors from younger glioblastoma patients, we received bisulfiteconverted DNA of ten glioblastoma patients (mean age 45 years) from the Department of Neuropathology, University of Heidelberg (W.M.).
IDH1 and H3F3A mutation status
Patients were screened for IDH1 and H3F3A mutations by direct sequencing of PCR products or immunohistochemistry. For sequencing analysis, the following primers were used:
Sequencing was performed by GATC Biotech, Konstanz, Germany. Immunohistochemistry detecting the IDH1R132H mutation was performed with mouse monoclonal antibody H09 (Dianova, Hamburg, Germany) on an automated immunostainer (BenchMark, Ventana Medical Systems, Tuscon, AZ, USA).
G-CIMP status
Methylation-specific PCRs (MSP) for 8 genes were performed as previously described 15 . A sample was considered G-CIMP positive when either DOCK5 was hypo-and 5 of the remaining 7 genes were hypermethylated or (in case of a hypermethylation of DOCK5) 6 out of the other 7 genes were hypermethylated. Unsupervised hierarchical clustering of methylation data was performed as described previously 15, 17 . Briefly, The probability of MGMT methylation was calculated as logit(y) = 4.3215 + 0.5271 * M-value(cg12434587) + 0.9265 * M-value(cg12981137). A probability cut-off at 0.358 was used. were considered statistically significant. Analyses were carried out using software R Version 2.14 27
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RESULTS
Study population
In total, 126 patients of the NOA-08 trial (termed NOA-08 biomarker cohort) were analyzed. months). Long-term OS data are demonstrating a group of patients with a considerably longer than average survival mainly in the temozolomide arm ( Figure 1a) . As expected from the increased median OS, these patients are overrepresented in our cohort due to enrichment of patients having undergone resection instead of biopsy.
Supplementary Table 3 lists the EFS and OS data for all 126 patients included in this study.
In the NOA-08 trial, histology (anaplastic astrocytoma vs. glioblastoma) did not significantly influence eventfree or overall survival 11 . This is recapitulated in the present biomarker cohort, where histology has no influence on event-free or overall survival. Kaplan-Meier plots are depicted in Supplementary Figure 1 .
Importantly, the predictive value of MGMT promoter methylation for response to temozolomide is recapitulated in this NOA-08 biomarker cohort (interaction p=0.03 (OS) and <0.001 (EFS)). In a Cox regression model,
MGMT promoter hypermethylation significantly prolonged EFS and OS in patients treated with temozolomide (p < 0.0001 and p=0.0014, respectively), while in the radiotherapy group, the influence of MGMT promoter methylation on survival was not significant (p=0.34 for EFS and p=0.14 for OS) (Figure 1b,c) .
IDH1 mutation, G-CIMP status and H3F3A mutations
In this study cohort, three patients carried an IDH1 mutation in their tumor tissue as determined by sequencing.
Of these, two patients had glioblastomas (out of 117 glioblastoma patients) and one had an anaplastic astrocytoma (out of 9 patients). The two glioblastoma patients had an overall survival of 582 and 924 days, respectively. This is above the median OS (272 (231-315 days) in the NOA-08 group, whereas the patient with an anaplastic astrocytoma had shorter than median survival (patient 37, OS 196 days). Notably, MGMT promoter analysis revealed hypermethylation in all 3 patients. On the other hand, only patient 110 received temozolomide as first-line treatment ( Table 2) .
To expand the sample size, we performed IDH1 immunohistochemistry on another 50 patients from the NOA-08 trial of whom only unstained paraffin-embedded slides, but no tumor DNA for further analysis, were available.
In this group, no IDH1(R132H) mutant tumor was detected. In summary, the low frequency of IDH1 mutations precludes a predictive role of this marker in elderly patients with glioblastoma, although individual patients may have a better course than the average.
In line with earlier reports demonstrating a strong correlation between IDH1 mutations and G-CIMP, the eightgene MSP panel revealed that these three IDH1 mutant patients were also G-CIMP positive. In the remaining IDH1 wildtype group of 123 samples, 4 samples could not be analyzed due to insufficient DNA left for bisulfite conversion and the other 119 were G-CIMP negative.
To screen our biomarker cohort for the recently described H3F3A K27M and G34R/V mutations, we amplified and sequenced a 170 bp fragment spanning the two mutation sites of the H3F3A gene in all 103 patients for which enough suitable DNA was left. We detected neither K27M nor G34R/V mutations in our cohort. between APNG methylated and APNG nonmethylated patients at a cut-off value of 10% (EFS, p=0.71) and 3%
APNG and PRDX1 methylation
(OS, p=0.42), respectively, which optimally separated the curves, did not yield a significant risk stratification, independent of treatment. When analyzing the predictive effect of APNG methylation in patients with a nonmethylated MGMT promoter who were treated with temozolomide, the low methylation levels precluded identification of a biologically meaningful cutpoint (7.2% for OS and 8.5% for EFS, respectively).
Since APNG has been proposed as a biomarker predictive for the benefit from temozolomide with average methylation levels varying between 30-40% (APNG expressers) and 70-80% (APNG non-expressers) 18 , we next aimed at investigating reasons for that discrepancy to our findings. To exclude APNG as a biomarker relevant only for younger patients, we also did MassARRAY analyses on 10 patients with an average age of 45 years.
This analysis yielded the same homogenously low methylation level as in the NOA-08 biomarker cohort (data not shown). In addition, Illumina 450k methylation arrays were performed for 22 patients from the NOA-08 biomarker collective. Further, samples from the TCGA project, which were analyzed on the same Illumina 450k 
Age-related survival differences
Given the paucity of positive prognostic factors in older glioblastoma patients, we sought to determine whether the relative absence of these known factors alone might explain the survival differences seen between different age groups using the TCGA data set. We determined G-CIMP (as a surrogate marker for IDH mutation) and MGMT promoter methylation status from Illumina HumanMethylation BeadChip data as previously described 15, 17, 21 and complemented these molecular data with clinical information from the TCGA database. In total, 170 patients had a complete clinical and molecular dataset. In this cohort, we detected 18 patients with a hypermethylator phenotype (10.5%), of which only 2 were older than 65 years. G-CIMP status was associated with a significantly prolonged survival (median overall survival 22. Figure 2b) . For further analysis, we excluded G-CIMP positive patients. Table 3 summarizes the baseline characteristics of both groups (G-CIMP negative patients < 65 and ≥ 65 years of age). Notably, the two groups showed no significant differences with regards to relevant prognostic or predictive parameters, albeit there was a trend towards a higher Karnofsky performance score in the younger cohort. Despite the balance between the groups, older patients had a significantly shorter overall survival (12. mutations (K27M and G34R/V) predominantly occurred in children and young adults and IDH mutations in young adults, while older patients mostly were classified into the remaining three subtypes (mesenchymal subtype, RTK 1 "PDGFRA" and RTK 2 "classic"). In agreement with this, IDH mutations are very rare in patients with malignant gliomas above the age of 60 14 . The lack of IDH mutations in these tumors might partially contribute to the worse prognosis of elderly patients with malignant gliomas, even though the analysis of the TCGA collective suggests that also other factors play a role in these age-related survival differences.
Along this line, we found only 3 IDH1 mutated patients in our cohort of 126 patients, and no H3F3A mutations.
In agreement with the recently discovered causative role of IDH mutations in epigenetic remodeling resulting in a G-CIMP phenotype, our 3 IDH1 mutated samples proved G-CIMP positive as well 30, 31 . With IDH1 mutations accounting for more than 90% of IDH mutations in glioma 13 , the causality between IDH mutation and the G-CIMP phenotype and the lack of a G-CIMP positive tumor in the remaining 119 IDH1 wildtype samples, we decided against testing for IDH2 mutations. Importantly, while the two glioblastoma patients carrying an IDH1 mutation and G-CIMP had an overall survival above average (see Table 2 ), 15 IDH wildtype / G-CIMP negative patients in this study population had a comparable or even longer overall survival than patient 110, who is IDH mutated / G-CIMP positive. Of these 15 patients one patient displayed a longer overall survival than the IDH mutated / G-CIMP positive patient 125 (see Supplementary Table 3 ).
The rationale for the further selection the biomarkers investigated in this study was to explain the survival heterogeneity seen in the NOA-08 trial population, where a group of patients had a considerably longer survival than average 11 . MGMT promoter methylation alone is not sufficient to account for this. In glioblastoma, key chromosomal, genetic and epigenetic aberrations have been defined, including EGFR amplification, TP53 mutation, CDK4 amplification, CDKN2A homozygous deletion or IDH mutations 12, 32 . However, with the notable exception of IDH mutations 13 , these molecular aberrations have no significant effect on survival 33 . With regard to the aim of our study, we therefore limited the selection of biomarkers to prognostically relevant markers.
A recent report demonstrated a role for the DNA repair enzyme APNG in conferring resistance to temozolomide in glioblastoma 18 . and non-expressers, differences in mean methylation levels across the investigated fragment (37 ± 5% for expressers and 77 ± 6% for non-expressers) were found. In vitro treatment of human glioblastoma cell lines with the demethylating agent 5-azacytidine resulted in up-regulation of APNG mRNA levels. This led the authors to propose that APNG expression is regulated through promoter hypermethylation. As the NOA-08 study and the present biomarker cohort clearly demonstrate the predictive effect of MGMT promoter hypermethylation described earlier 34 , we sought to determine if APNG methylation also has the predictive value as proposed before. In contrast to Agnihotri and colleagues, we performed MassARRAY analysis of the same fragment, a well established technique for quantitative assessment of methylation 20 . Surprisingly, we only detected <20% levels of APNG promoter methylation across all samples and CpG units (Figure 2 ) and did not observe the separation of patients into two groups. Since methylation is known to be at least partially age-dependent 35 , we expanded our MassARRAY analysis to include ten younger glioblastoma patients (mean age 45 years) and obtained similar results. Our findings were confirmed through a technically and (partly) biologically independent analysis of Illumina 450k methylation arrays of 22 NOA-08 samples and 74 TCGA samples. The low methylation of APNG is no age-specific effect, as evidenced by the TCGA samples, which include patients aged between 23 and 85 years (mean age 61 years) and showed homogenously low methylation levels across all samples. Furthermore, the methylation-specific predictive effect of MGMT promoter methylation is highly significant in both our subset and the whole NOA-08 cohort. A possible explanation for the conflicting results regarding APNG methylation may lie in the use of the non-quantitative bisulfite sequencing, which requires clonal amplification prior to sequencing, thus introducing an additional step for potential bias. Our APNG amplicon was marginally larger than that examined by Agnihotri et al. (233 bp vs. 193 bp), yet addressed exactly the same CpGs (Figure 2c) . We carefully re-inspected our amplicon sequence with respect to possible SNPs in primer sequences and GC-content, being 41% after bisulfite treatment in case all CpGs would be methylated, and found no obvious hint for any PCR bias in our setting. Further studies will be required to assess the role of epigenetic regulation in APNG expression.
Analysis of PRDX1 promoter methylation, a novel marker for sensitivity towards temozolomide or radiotherapy, yielded no significant effect on survival. This is in line with the original report on PRDX methylation, which suggested that hypermethylation mostly occurs in oligodendroglial tumors and secondary glioblastomas 19 .
Although the biomarker cohort analyzed in the present study was representative for the NOA-08 study population ( Table 1) To assess the influence of age on survival, we analyzed survival in a large cohort from the TCGA, which was well matched for all relevant prognostic factors. However, the median survival times of the TCGA collective are subject to a selection bias, e.g. due to the tissue requirements for molecular analysis (exemplified by a 90% resection rate, Table 3 versus 60% in NOA-08 11 ) and thus cannot be externally compared, e.g. to the NOA-08 survival times. Nonetheless, in the intragroup comparison, patients aged ≥ 65 years still had significantly shorter overall survival times than their younger counterparts.
In summary, favorable prognostic biomarkers such as IDH or H3F3A mutation, G-CIMP or PRDX1 methylation are virtually absent in malignant astrocytic tumors of the elderly which may partially account for the worsened prognosis of these patients. However, even in G-CIMP negative (and hence IDH wild-type) tumors, which are matched for known prognostic factors, older patients have a significantly shorter overall survival. On the other hand, several long-term surviving patients in our cohort exist which lack the aforementioned molecular markers and sometimes even MGMT promoter hypermethylation. These two observations strongly hint at the existence of so-far unknown prognostic factors in these patients. Further studies are necessary to broaden our insight into the molecular aberrations in elderly patients in order to step-wise replace chronological age as the most important negative prognostic marker and potentially therapy-decisive variable in malignant astrocytomas with defined and hopefully actionable molecular mechanisms.
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